Main navigation

Products we regulate
Product safety
How we regulate
Guidance and resources
News and Community
About us

Bristol-Myers Squibb Australia Pty Ltd

Regulatory activities for this sponsor.

Loading...

ARTG (60) ARTG (60)
Cancellation by sponsor (41) Cancellation by sponsor (41)
Australian Public Assessment Report (AusPAR) (31)
Prescription medicine registration (29)
Designation or determination (5) Designation or determination (5)
Prescription medicine evaluation (5) Prescription medicine evaluation (5)
Prescription medicine decision summary (2)
Section 14, TGO91 consent (2) Section 14, TGO91 consent (2)

2025 (3) 2025 (3)
2024 (11) 2024 (11)
2023 (6) 2023 (6)
2022 (18) 2022 (18)
2021 (9) 2021 (9)
2020 (15) 2020 (15)
2019 (4) 2019 (4)
2018 (23) 2018 (23)
2017 (18) 2017 (18)
2016 (5) 2016 (5)
2015 (14) 2015 (14)
2014 (4) 2014 (4)
2013 (7) 2013 (7)
2012 (5) 2012 (5)
2011 (10) 2011 (10)
2010 (3) 2010 (3)
2009 (3) 2009 (3)
2007 (12) 2007 (12)
2004 (1) 2004 (1)
1993 (2) 1993 (2)
1991 (2) 1991 (2)

Search

Sponsor content

175 result(s) found, displaying 31 to 40

REBLOZYL luspatercept 25 mg powder for injection vial (334510)

30 August 2021

ARTG

Australian Register of Therapeutic Goods (ARTG) information for REBLOZYL luspatercept 25 mg powder for injection vial.
REBLOZYL luspatercept 75 mg powder for injection vial (334511)

30 August 2021

ARTG

Australian Register of Therapeutic Goods (ARTG) information for REBLOZYL luspatercept 75 mg powder for injection vial.
Camzyos

13 October 2022

Prescription medicine decision summary

Camzyos (mavacamten) is approved to treat cardiomyopathy.
OPDUALAG (Bristol-Myers Squibb Australia Pty Ltd)

5 October 2022

Prescription medicine registration

Active ingredients: nivolumab, relatlimab.
CAMZYOS (Bristol-Myers Squibb Australia Pty Ltd)

15 September 2022

Prescription medicine registration

Active ingredients: mavacamten.
OPDIVO (Bristol-Myers Squibb Australia Pty Ltd)

14 July 2022

Prescription medicine registration

Active ingredients: nivolumab.
DAKLINZA daclatasvir (as dihydrochloride) 30 mg tablet blister Cancelled under Section 30(1)(c) of the Act

7 March 2022

Cancellation by sponsor

Requested by Bristol-Myers Squibb Australia Pty Ltd
DAKLINZA daclatasvir (as dihydrochloride) 60 mg tablet blister Cancelled under Section 30(1)(c) of the Act

7 March 2022

Cancellation by sponsor

Requested by Bristol-Myers Squibb Australia Pty Ltd
OPDIVO (Bristol-Myers Squibb Australia Pty Ltd)

31 January 2022

Prescription medicine registration

Active ingredients: nivolumab.
OPDIVO (Bristol-Myers Squibb Australia Pty Ltd)

31 January 2022

Prescription medicine registration

Active ingredients: nivolumab.

Pages

First page
Previous page
Page 1
Page 2
Page 3
Current page 4
Page 5
Page 6
Page 7
Page 8
Page 9
…
Next page
Last page

Is there anything wrong with this page?

Help us improve this page

What were you doing? (mandatory)

What went wrong? (mandatory)

Leave this field blank

Using our website

Accessibility
Privacy
Security
Disclaimer
Copyright
Freedom of information

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control - external site
State and territory contacts

Connect with us

Subscribe to updates
Contact us
Facebook - external site
(formerly Twitter) - external site
Youtube - external site
Instagram - external site
LinkedIn - external site

Help us improve

We are always looking for ways to improve our website.

Provide feedback - external site

The Department of Health and Aged Care acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.

Bristol-Myers Squibb Australia Pty Ltd

Type

Date

Help us improve this page